Zobrazeno 1 - 10
of 156
pro vyhledávání: '"Timothy J Perren"'
Autor:
Myria Nikolaou, Timothy J. Perren, Gia Nemsadze, Richard D. Baird, Robert McEwen, Daniel Stetson, Duncan Wheatley, A.M. Brunt, Hayley Cartwright, Max McLaughlin-Callan, Jean-Marc Ferrero, Peter Schmid, Cheryl Lawrence, Jacinta Abraham, Nicholas C. Turner, László Mangel, Melissa Phillips, Matthew Burgess, Peter Hall, John Conibear, Andrew Foxley, Aaron Prendergast, Kelly Mousa, Robert Stein, Yeon Hee Park, Javier Cortes, Stephen Chan, Elza C. de Bruin, Brian Dougherty
Publikováno v:
Cancer Research. 81:PD1-11
Background: In the PAKT study, addition of the oral AKT inhibitor capivasertib to 1st-line paclitaxel therapy for metastatic TNBC resulted in significantly longer progression-free survival (PFS; primary endpoint; Schmid, J Clin Oncol 2020). The strat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a130894bef5287d61428650111815a23
https://doi.org/10.1158/1538-7445.sabcs20-pd1-11
https://doi.org/10.1158/1538-7445.sabcs20-pd1-11
Autor:
Timothy J. Perren, Rosemary Lord, Jane Hook, Ian A. McNeish, Christopher J. Poole, Jonathan A. Ledermann, Helena M. Earl, Sarah P. Blagden, Adrian Cook, Jae Weon Kim, Graham Dark, Andrew R Clamp, Marcia Hall, Dearbhaile M. O'Donnell, Richard Kaplan, Ian R. White, Lesley Howells, Andrew Dean, Elizabeth C. James
Publikováno v:
Lancet Oncol
The Lancet. Oncology
The Lancet. Oncology
Summary Background The ICON8 study reported no significant improvement in progression-free survival (a primary endpoint) with weekly chemotherapy compared with standard 3-weekly treatment among patients with epithelial ovarian cancer. All ICON8 patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aae8d60ca6ad6844f064f0d3022fd69c
https://doi.org/10.1016/s1470-2045(20)30218-7
https://doi.org/10.1016/s1470-2045(20)30218-7
Autor:
Helena M. Earl, Robert E. Coleman, Timothy J. Perren, T.R. Jeffry Evans, Janine Mansi, Joanna Dunlop, Chara Stavraka, David Cameron, Robert C. F. Leonard
Publikováno v:
Cancer Research. 80:P2-16
Aim: The aim of this study was to compare the long-term outcome of women with primary or locally advanced breast cancer randomised to receive either doxorubicin and cyclophosphamide (AC) or doxorubicin and docetaxel (AD) as primary chemotherapy. Pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::55d97d37f4140fb94d03062e87eb3763
https://doi.org/10.1158/1538-7445.sabcs19-p2-16-15
https://doi.org/10.1158/1538-7445.sabcs19-p2-16-15
Autor:
Hani Gabra, Dearbhaile M. O'Donnell, S. P. Stenning, Christopher Coyle, Jane Hook, Rosalind Glasspool, Graham Dark, Rachel Jones, Susana Banerjee, Jonathan A. Ledermann, Helena M. Earl, Andrew R Clamp, Adrian Cook, Marcia Hall, Timothy J. Perren, Sarah Williams, Rosemary Lord, Mahesh K. B. Parmar, Gosala S. Gopalakrishnan, Ann Marie Swart, Jae Weon Kim, Sudha Sundar, James D. Brenton, Elizabeth C. James, Raj Naik, Richard Kaplan, Iain A. McNeish, Andrew Dean, Sarah P. Blagden
Publikováno v:
Lancet (London, England)
Background:\ud Carboplatin and paclitaxel administered every 3 weeks is standard-of-care first-line chemotherapy for epithelial ovarian cancer. The Japanese JGOG3016 trial showed a significant improvement in progression-free and overall survival with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2674f0ee7d22ba66f23b58342496dee2
https://doi.org/10.1016/s0140-6736(19)32259-7
https://doi.org/10.1016/s0140-6736(19)32259-7
Autor:
Clare Green, Gianfilippo Bertelli, Marcia Hall, Chit Cheng Yeoh, Steve Chan, Timothy J. Perren, Louise Li, Agnes Ograbek, Rachel Jones, Jurjees Hasan
Publikováno v:
International Journal of Gynecologic Cancer. 30:213-220
ObjectiveTwo randomized phase III trials demonstrated the efficacy and safety of combining bevacizumab with front-line carboplatin/paclitaxel for advanced ovarian cancer. The OSCAR (NCT01863693) study assessed the impact of front-line bevacizumab-con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbd3841910d44e169a877ba3f16c407e
https://doi.org/10.1136/ijgc-2019-000512
https://doi.org/10.1136/ijgc-2019-000512
Autor:
W. Sopwith, Timothy J. Perren, A Lee, N. Ahat-Donker, M. Riaz, M. Thompson, M. Myland, Stuart J. Turner, Chris Twelves, S. Cheeseman, Geoff Hall
Publikováno v:
Cancer Research. 79:P4-13
OBJECTIVES: Outcomes for patients with MBC vary according to disease phenotype and treatment history. We present UK real-world patient characteristics, treatment patterns and outcomes for patients with HR+/HER2- BC treated at a single cancer center.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1456926274965445931be212533e3849
https://doi.org/10.1158/1538-7445.sabcs18-p4-13-14
https://doi.org/10.1158/1538-7445.sabcs18-p4-13-14
Autor:
David L. Buckley, Barbara Dall, Andrew M. Hanby, Thomas A. Hughes, Timothy J. Perren, David Dodwell, Nisha Sharma, Daniel Wilson, Leonidas Georgiou, Isabelle M Farrow, Laura M Windel, William Stevens
Publikováno v:
The British Journal of Radiology
Objectives: Better markers of early response to neoadjuvant chemotherapy (NACT) in patients with breast cancer are required to enable the timely identification of non-responders and reduce unnecessary treatment side-effects. Early functional imaging
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::138de2cd25744fc156504f1eb04574ab
http://europepmc.org/articles/PMC8248209
http://europepmc.org/articles/PMC8248209
Autor:
Gordon C Jayson, A C Embleton-Thirsk, Stan B. Kaye, Timothy J. Perren, M K B Parmar, E Deane, J. A. Ledermann, Antonio González-Martín, H. Hirte, Michelle Margaret Vaughan, Laura Farrelly, Richard Kaplan, Amit M. Oza, Ann Marie Swart, G. J. S. Rustin, B Popoola, Michael Friedlander
Publikováno v:
ESMO Open
Background Cediranib, an oral anti-angiogenic VEGFR 1-3 inhibitor, was studied at a daily dose of 20 mg in combination with platinum-based chemotherapy and as maintenance in a randomised trial in patients with first relapse of ‘platinum-sensitive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d15558f2ba412cbdd748ee1254af17b
https://ueaeprints.uea.ac.uk/id/eprint/79569/
https://ueaeprints.uea.ac.uk/id/eprint/79569/
Autor:
Julien Péron, Michel Tod, Christophe Sajous, Adrian Cook, Gilles Freyer, Timothy J. Perren, Olivier Colomban, Alexandra Leary, Benoit You
Publikováno v:
JNCI Cancer Spectrum
Bevacizumab is approved as a maintenance treatment in first-line setting in advanced-stage III-IV ovarian cancers, because GOG-0218 and ICON-7 phase III trials demonstrated progression-free survival benefits. However, only the subgroup of patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23c797afc88f0ce5d9462aa2626a5708
Publikováno v:
Magnetic Resonance in Medicine. 81:1955-1963
Purpose: To measure the arterial input function (AIF), an essential component of tracer kinetic analysis, in a population of patients using an optimized dynamic contrast-enhanced imaging sequence and to estimate inter- and intra-patient variability.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97aa8440ef4b6db2ff4a3c14e6d2f08d
https://doi.org/10.1002/mrm.27524
https://doi.org/10.1002/mrm.27524